Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Yousif Capital Management LLC

Yousif Capital Management LLC boosted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 3.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 52,224 shares of the biotechnology company’s stock after purchasing an additional 1,659 shares during the period. Yousif Capital Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,598,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Arrowhead Pharmaceuticals by 58.2% in the third quarter. FMR LLC now owns 4,308,903 shares of the biotechnology company’s stock valued at $115,780,000 after buying an additional 1,584,425 shares in the last quarter. Invesco Ltd. lifted its position in shares of Arrowhead Pharmaceuticals by 9.6% during the third quarter. Invesco Ltd. now owns 2,443,038 shares of the biotechnology company’s stock worth $65,644,000 after purchasing an additional 214,618 shares in the last quarter. Avidity Partners Management LP boosted its stake in shares of Arrowhead Pharmaceuticals by 15.0% in the third quarter. Avidity Partners Management LP now owns 1,063,897 shares of the biotechnology company’s stock valued at $28,587,000 after purchasing an additional 138,897 shares during the period. Jump Financial LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 314.2% in the third quarter. Jump Financial LLC now owns 114,433 shares of the biotechnology company’s stock valued at $3,075,000 after purchasing an additional 86,807 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its stake in Arrowhead Pharmaceuticals by 26.6% during the 3rd quarter. Rafferty Asset Management LLC now owns 297,755 shares of the biotechnology company’s stock worth $8,001,000 after buying an additional 62,542 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Up 4.1 %

ARWR stock opened at $24.13 on Friday. The company’s 50 day moving average is $27.60 and its two-hundred day moving average is $28.76. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $20.67 and a twelve month high of $42.48. The stock has a market cap of $2.99 billion, a P/E ratio of -8.68 and a beta of 0.78.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). The firm had revenue of $3.55 million during the quarter, compared to analyst estimates of $35.60 million. Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 90.77%. The firm’s revenue for the quarter was down 94.3% compared to the same quarter last year. During the same period last year, the company earned ($0.39) earnings per share. On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on ARWR shares. Citigroup raised their price target on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research report on Wednesday, February 7th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, February 8th. Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $50.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $50.80.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu bought 1,000 shares of the stock in a transaction on Monday, March 18th. The shares were bought at an average cost of $27.49 per share, for a total transaction of $27,490.00. Following the purchase, the director now owns 31,680 shares of the company’s stock, valued at approximately $870,883.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CFO Kenneth Allen Myszkowski sold 40,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total value of $1,407,600.00. Following the completion of the transaction, the chief financial officer now owns 400,600 shares in the company, valued at approximately $14,097,114. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hongbo Lu purchased 1,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, March 18th. The shares were bought at an average price of $27.49 per share, with a total value of $27,490.00. Following the completion of the transaction, the director now owns 31,680 shares in the company, valued at approximately $870,883.20. The disclosure for this purchase can be found here. 4.50% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.